These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 16160477)

  • 41. Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
    Kyriazoglou A; Pagkali A; Kotsantis I; Economopoulou P; Kyrkasiadou M; Moutafi M; Gavrielatou N; Anastasiou M; Boulouta A; Pantazopoulos A; Giannakakou M; Digklia A; Psyrri A
    Cancer Treat Rev; 2024 Apr; 125():102716. PubMed ID: 38492514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liposarcoma of the pleural cavity.
    Kawai T; Nakashima H; Washimi K; Yokose T; Matsuo T; Nakayama M; Shinohara N; Kuroda H; Ishida K; Akiba J; Ishikawa M; Urabe S; Shiraishi J; Shiraishi T; Sakamoto A; Matsukuma S
    Hum Pathol; 2023 Jun; 136():105-113. PubMed ID: 37023867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours.
    Dei Tos AP; Doglioni C; Piccinin S; Sciot R; Furlanetto A; Boiocchi M; Dal Cin P; Maestro R; Fletcher CD; Tallini G
    J Pathol; 2000 Apr; 190(5):531-6. PubMed ID: 10727978
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
    Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
    J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Negative MDM2/CDK4 immunoreactivity does not fully exclude MDM2/CDK4 amplification in a subset of atypical lipomatous tumor/ well differentiated liposarcoma.
    Machado I; Vargas AC; Maclean F; Llombart-Bosch A
    Pathol Res Pract; 2022 Apr; 232():153839. PubMed ID: 35303521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liposarcomatous differentiation in malignant phyllodes tumours is unassociated with MDM2 or CDK4 amplification.
    Lyle PL; Bridge JA; Simpson JF; Cates JM; Sanders ME
    Histopathology; 2016 Jun; 68(7):1040-5. PubMed ID: 26542423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Atypical lipomatous tumor/well differentiated liposarcoma and related mimics with updates. When is molecular testing most cost-effective, necessary, and indicated?
    Kilpatrick SE
    Hum Pathol; 2024 May; 147():82-91. PubMed ID: 38135062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of the MDM2/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma.
    Yamashita K; Kohashi K; Yamada Y; Akatsuka S; Ikuta K; Nishida Y; Toyokuni S; Oda Y
    Genes Chromosomes Cancer; 2021 Jan; 60(1):26-37. PubMed ID: 33111425
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
    Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G
    Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Can HMGI-C be used as an aid with MDM2 and CDK4 to differentiate liposarcoma subtypes from their mimics?
    Alshenawy H
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):1073-81. PubMed ID: 23529275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation.
    Kanoe H; Nakayama T; Murakami H; Hosaka T; Yamamoto H; Nakashima Y; Tsuboyama T; Nakamura T; Sasaki MS; Toguchida J
    Anticancer Res; 1998; 18(4A):2317-21. PubMed ID: 9703873
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MDM4 amplification in atypical lipomatous tumors/well-differentiated liposarcoma: Private event or alternative oncogenic mechanism?
    Gruel N; El Zein S; Tzanis D; Nicolas N; Maraval A; Fieffe C; Bonvalot S; Caly M; Fuhrmann L; Ait Rais K; Jovelin S; Bonnet C; Pierron G; Watson S
    Genes Chromosomes Cancer; 2023 Jun; 62(6):367-372. PubMed ID: 36744846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma.
    Coindre JM; Mariani O; Chibon F; Mairal A; De Saint Aubain Somerhausen N; Favre-Guillevin E; Bui NB; Stoeckle E; Hostein I; Aurias A
    Mod Pathol; 2003 Mar; 16(3):256-62. PubMed ID: 12640106
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paratesticular Dedifferentiated Liposarcoma with Epithelioid Features: A Diagnostic Pitfall.
    Patton A; McKenney JK; Alruwaii FI; Angulo KA; Fuller LD; Calvaresi E; Billings SD; Goldblum JR; Fritchie KJ
    Int J Surg Pathol; 2023 Aug; 31(5):721-727. PubMed ID: 36113458
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel sclerosing atypical lipomatous tumor/well-differentiated liposarcoma in a 7-year-old girl: report of a case with molecular confirmation.
    Peng R; Chen H; Yang X; Zhang X; Zhang Z; He X; Zhang H
    Hum Pathol; 2018 Jan; 71():41-46. PubMed ID: 28705709
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Chromogenic In Situ Hybridization and Fluorescence In Situ Hybridization for the Evaluation of MDM2 Amplification in Adipocytic Tumors.
    Mardekian SK; Solomides CC; Gong JZ; Peiper SC; Wang ZX; Bajaj R
    J Clin Lab Anal; 2015 Nov; 29(6):462-8. PubMed ID: 25132285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. p16 Immunohistochemistry is Less Useful Than MDM2 and CDK4 to Distinguish Dedifferentiated Liposarcomas From Other Retroperitoneal Mimics.
    Kang Y; Horvai AE
    Appl Immunohistochem Mol Morphol; 2017 Jan; 25(1):58-63. PubMed ID: 26509911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.
    Dantey K; Schoedel K; Yergiyev O; Bartlett D; Rao UNM
    Hum Pathol; 2017 Aug; 66():86-92. PubMed ID: 28300575
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-grade Osteosarcomatous Dedifferentiation of an Atypical Lipomatous Tumor in a Pediatric Patient.
    Kukull BJ; Khalighi MA; Gundle KR; Hansford BG; Corless CL; Davis JL
    Pediatr Dev Pathol; 2020; 23(3):240-246. PubMed ID: 31739757
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma.
    Erickson-Johnson MR; Seys AR; Roth CW; King AA; Hulshizer RL; Wang X; Asmann YW; Lloyd RV; Jacob EK; Oliveira AM
    Mod Pathol; 2009 Dec; 22(12):1541-7. PubMed ID: 19820690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.